Last reviewed · How we verify
rhPro-UK
rhPro-UK is a recombinant human prokineticin-2 analogue that acts as a prokineticin-2 receptor agonist.
rhPro-UK is a recombinant human prokineticin-2 analogue that acts as a prokineticin-2 receptor agonist. Used for Treatment of solid tumors.
At a glance
| Generic name | rhPro-UK |
|---|---|
| Sponsor | Tasly Biopharmaceuticals Co., Ltd. |
| Drug class | prokineticin-2 receptor agonist |
| Target | prokineticin-2 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
rhPro-UK binds to the prokineticin-2 receptor, activating downstream signaling pathways that promote angiogenesis and potentially therapeutic effects in various diseases.
Approved indications
- Treatment of solid tumors
Common side effects
- Injection site reaction
- Fatigue
- Nausea
Key clinical trials
- Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) (PHASE3)
- Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits (PHASE4)
- Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer (PHASE3)
- Intravenous Thrombolysis and NOAC (PHASE3)
- Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months (PHASE3)
- ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE) (PHASE3)
- rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) (PHASE3)
- A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhPro-UK CI brief — competitive landscape report
- rhPro-UK updates RSS · CI watch RSS
- Tasly Biopharmaceuticals Co., Ltd. portfolio CI